Abstracts tagged "atherosclerosis and biomarkers"

Abstract Number: 716 • 2018 ACR/ARHP Annual Meeting
Soluble CD163 Is a Biomarker Associated with Accelerated Carotid Atheroma in SLE Patients at Otherwise Low Risk for Cardiovascular Disease
Clemence David¹, Gillian Divard¹, Rachid Abbas¹, Brigitte Escoubet¹, Marie-Paule Chauveheid¹, Diane Rouzaud¹, Anne Boutten¹, Thomas Papo¹, Monique Dehoux¹ and Karim Sacre², ¹Université Paris-Diderot, Paris, France, ²Bichat Hospital, Paris Diderot University, Paris, France
Background/Purpose: Our study aimed to determine whether sCD163, a soluble macrophage marker upregulated in numerous inflammatory disorders, might be predictive of accelerated atherosclerosis associated with…
Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Maureen A. McMahon¹, Jennifer M. Grossman², Lori Sahakian³, Christina Charles-Schoeman⁴, John Fitzgerald¹, Mihaela Taylor⁴, Alan Gorn¹, Eloise Olmos¹, Daniel J. Wallace⁵, Bevra H Hahn^1,4 and Brian Skaggs⁴, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].